Document:

Exhibit 10(d)

FIRST AMENDMENT OF
EXECUTIVE VICE PRESIDENT EMPLOYMENT AGREEMENT

This
FIRST AMENDMENT OF THE EXECUTIVE VICE PRESIDENT EMPLOYMENT AGREEMENT
(hereinafter this “Agreement”) is made this          
day of March, 2007, between LAMONT THOMAS, an individual residing at 5512 Aspen
Dale Court, Ellicott City, Maryland 21403 (“Mr. Thomas”) and CommerceFirst
Bancorp, Inc., a Maryland Corporation, with its principal place of business at
1804 West Street, P.O. Box 2249, Annapolis, Maryland 21404, its successors, and
assigns (hereinafter the “Holding Company”), and CommerceFirst Bank, a Maryland
Commercial Banking Corporation, with its principal office at  804 West Street, P.O. Box 2249, Annapolis,
Maryland 21404 (hereinafter the “Bank”).

RECITALS

WHEREAS,
the Holding Company entered into an Executive Vice President Employment
Agreement with Mr. Thomas on August 1, 1999 which was set to expire on August
1, 2004 (hereinafter the “Employment Agreement”); and

WHEREAS,
The Holding Company entered into an Extension of the Executive Vice President
Employment Agreement with Mr. Thomas (hereinafter the “Employment Agreement
Extension”) on                         
which extended the term of Mr. Thomas’ employment with the Bank from August
1, 2004 to August 15, 2009; and

WHEREAS,
The Holding Company, the Bank and Mr. Thomas have agreed to amend and modify
Mr. Thomas’ current Employment Agreement.

NOW
THERFORE, for the reasons set forth above and in consideration of the mutual
promises and agreements set forth below, the Holding Company, the Bank and Mr.
Thomas agree as follows:

1.1           COO/CFO Transition Plan:  The Holding Company, the Bank and Mr. Thomas
hereby agree that it is in the best interest of the Bank to hire a long term
Chief Financial Officer (hereinafter “CFO”) and to implement a COO/CFO
transition plan.  During the transition
phase, Mr. Thomas agrees to continue to serve as Executive Vice President and
Chief Operating Officer, and assist the new CFO on a full time basis.

1.2           Current
Employment End Date:  Mr. Thomas’
full time position as Executive Vice President and Chief Operating Officer with
the Bank will end on December 31, 2007.

1.3           Consulting
Agreement and  Term:  Beginning January 1, 2008 and ending
on December 31, 2011 Mr. Thomas shall serve as a consultant and advisor
to CommerceFirst Bank and CommerceFirst Bancorp upon specific terms and
conditions to be agreed upon between Mr. Thomas and the Bank.

 1
 

 

1.4           Consulting Agreement Compensation:  Mr. Thomas’ compensation  for the foregoing Consulting Agreement will
be Fifty Two Thousand Dollars ($52,000.00) per annum payable in
accordance with the Bank’s regular payroll practices.

1.5           Change in Control:

1.5.1      The provisions of Article IX “Change in
Control” of the Employment Agreement will continue until August 15, 2009,
to be calculated at Mr. Thomas’ 2007 annual base compensation rate, if
applicable.

1.5.2      The Change in Control provisions of
Article IX of the Employment Agreement shall be deemed to apply:

(a)         To any Change in Control transaction
which closes during the term of this First Amendment or any subsequent
amendments; or

(b)         To any proposed Change in Control
transaction which is formally reported to and discussed with the Board of
Directors by Management or investment bankers or other parties who may report
such proposed transaction to the Board of Directors, if:

(1)         Such transaction in fact closes during
the term of this First Amendment or within Twelve (12) months after the end of
such term;

(2)         Unless such transaction which was
formally reported to and discussed by the Board of Directors during the term of
this First Amendment is subsequently closed by the Board of Directors, whether
or not a transaction with such party or parties is reopened and consummated at
a later time.

(c)         To any Change in Control transaction
which arises from a formal decision by the Board of Directors during the term
of this First Amendment to engage an investment banker(s) for the purpose of
soliciting offers for a transaction which would otherwise qualify as a Change
in Control provided such transaction closes within Twelve (12) months after the
end of the term of this First Amendment.

1.6           Compliance with IRS Section 409A.  Notwithstanding any other provision of this
Agreement, all of its terms and conditions, including but not limited to the
Change in Control Compensation and all other Compensation and Benefits sections
shall be subject to and in compliance with the provisions of Internal Revenue
Code Section 409A and the regulations promulgated thereunder.  To the extent any provision of this Agreement
is deemed in the reasonable judgment of legal counsel or auditors of the Bank,
or by any federal or state banking or securities regulators with jurisdiction
over the Bank or the Holding Company to be in violation of IRC Section 409A,
then the terms of this Agreement may be modified or amended by the Bank and/or
the Holding Company so as to be in compliance with IRC Section 409A and the
regulations promulgated thereunder.  Mr.
Thomas agrees in advance to any such modifications to this Agreement which may
be required or advised in the reasonable judgment of 

 2
 

legal counsel or
auditors of the Bank or by any federal or state banking or securities
regulators with jurisdiction over the Bank or the Holding Company.

1.7         Board & Committee Positions:
Mr. Thomas will retain a seat on the CommerceFirst Bancorp Board (subject to
expected shareholder approval at annual meetings), CommerceFirst Bank Board,
and CommerceFirst Bank Executive Committee. 
Mr. Thomas may also serve on such other committees, as the Bancorp of
Bank Boards may with Mr. Thomas’ agreement designate.  Mr. Thomas will not receive director fees
during the term of this Agreement.  After
this Agreement expires, Mr. Thomas will receive standard director fees.

1.8         Continuation of Employment Agreement
Terms.  Except as expressly amended
or modified by this Agreement, or necessarily by implication modified by this
Agreement, all other terms and conditions of Mr. Thomas’ Employment Agreement,
as previously extended, shall remain in full force and effect.

1.9         Contingency.  The terms and conditions of this Agreement
are contingent, at the option of CommerceFirst Bank, upon the Bank reaching an
agreement for the hiring of a new COO/CFO on or before June 30, 2007.  In the event the Bank is unable to reach such
an agreement within such time frame, the terms and conditions of this Agreement
may at the option of the Bank be declared void and Mr. Thomas’ original
Employment Agreement, as amended, shall remain in full force and effect.

IN
WITNESS WHEREOF, this Agreement has been executed by the Bank and Mr. Thomas as
of the day and year first above written.

	
  

  	
   

  	
  HOLDING COMPANY:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  	
  Milton D. Jernigan, II, Chairman

  	
  Date

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BANK:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  	
  Milton D. Jernigan, II, Chairman

  	
  Date

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  MR. THOMAS:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  	
  Lamont Thomas

  	
  Date

  
										

 

 3Exhibit 10.2

TERMINATION AGREEMENT

This Termination Agreement terminates the Amended and Restated
Collaboration Agreement dated May 31, 2002, as previously amended (the “Collaboration
Agreement”) by and between Genzyme Corporation, with its principal office at
500 Kendall Street, Cambridge, Massachusetts, 02142 (“Genzyme”), and Dyax
Corp., with a principal office at 300 Technology Square, Cambridge,
Massachusetts, 02139 (“Dyax”), and is effective as of February 20, 2007 (“Termination
Effective Date”).  Terms not otherwise
defined herein shall have the respective meanings attributed to them in the
Collaboration Agreement.

WHEREAS, Genzyme and Dyax are parties to the Collaboration Agreement,
pursuant to which the parties agreed to collaborate in developing DX-88 for the
treatment of hereditary angioedema and other inflammatory diseases; and

WHEREAS, Genzyme and Dyax now wish to terminate the Collaboration
Agreement on the terms and conditions set forth below;

NOW, THEREFORE, in consideration of the promises and agreements set
forth herein, and for other good and valuable consideration, Genzyme and Dyax
hereby agree as follows:

1.                                       Termination.  The Collaboration Agreement
shall be terminated as of the Termination Effective Date.  Except as specifically set forth in this
Termination Agreement, neither party shall have any further obligations to the
other party after the Termination Effective Date.

2.                                       Payment to Dyax.  At
the Closing (as such term is defined in the Securities Sale Agreement being
executed by Dyax and Genzyme on the date hereof), Genzyme shall make a capital
contribution to Dyax-Genzyme LLC (the “LLC”) in the amount of Seventeen Million
United States Dollars (U.S. $17,000,000).

3.                                       Purchase of Genzyme’s Interest in LLC.  At
the Closing (as such term is defined in the Securities Sale Agreement being
executed by Dyax and Genzyme on the date hereof), Dyax shall purchase Genzyme’s
49.99% interest in Dyax-Genzyme LLC for 4,400,000 shares of Dyax common stock,
$0.01 par value per share.  Upon receipt
of such consideration, Genzyme shall assign all of its interest in Dyax-Genzyme
LLC to Dyax, and Dyax shall dissolve Dyax-Genzyme LLC promptly thereafter.  The parties will execute any and all
documents necessary to effectuate this transaction.

4.                                       Program Costs.  Each
of Dyax and Genzyme agree to submit to the other party within forty-five (45)
days after the Termination Effective Date a final statement of their respective
Program Costs incurred on behalf of the LLC through the Termination Effective
Date and each agrees to review and pay the other party the amounts properly due
thereunder in accordance with the Collaboration Agreement.

5.                                       Transition Services. 
Genzyme and Dyax shall negotiate in good faith a Transition Services
Agreement, which will set forth all of the transition services to be provided
by Genzyme after the Termination Effective Date and for a reasonable period of
time thereafter.  The Transition Services
Agreement will provide that (i) Dyax shall pay Genzyme for such transition
services at a cost to Dyax determined on the same basis (the “Program Cost
Basis”) as Genzyme has determined Program Costs under the Collaboration
Agreement prior to the Termination Effective Date, (ii) all agreements between
Genzyme and third parties relating to the Program shall be assigned to Dyax and
(iii) all agreements between Dyax and Genzyme relating to the Collaboration
Agreement shall be terminated.  The
parties

will
use reasonable efforts to execute such Transition Services Agreement within
forty-five (45) calendar days after the Termination Effective Date.  Until the Transition Services Agreement is
executed, but for no longer than sixty (60) calendar days after the Termination
Effective Date, Genzyme will continue to provide in-kind support for the
Program at the level provided prior to the Termination Effective Date on the
Program Cost Basis.

6.                                       Intellectual Property.  (i)
All licenses granted by Genzyme pursuant to Article 3 of the Collaboration
Agreement are hereby revoked, (ii) Genzyme hereby grants Dyax a worldwide,
exclusive, royalty-free, irrevocable right and license, with the right to
grant sublicenses, under the Genzyme Patent Rights, the Genzyme Technology,
rights in Joint Technology and Joint Patent Rights, and Manufacturing Know-How
to develop, make, have made, use, offer for sale, sell, have sold, import and
export Collaboration Products in the Field, and (iii) any Regulatory Approvals
filed and any trademarks relating exclusively to the Program registered in the
name of an entity other than the LLC or Dyax shall be transferred or assigned
to Dyax.  Each party agrees to execute
and deliver promptly any and all documents reasonably requested by the other
party to effect the foregoing.

7.                                       Survival.  The following sections of the
Collaboration Agreement shall survive after the Termination Effective
Date:  Article I (Definitions), Section
3.4 (Reservation of Rights), Section 4.6 (Books of Account; Audit), Section 9.1
(Ownership) (other than Subsection 9.1.2), Section 9.3 (Cooperation), Section
9.5 (No Other Technology Rights), Article 10 (Confidentiality) (except that
Dyax shall have no obligation under the last sentence of Section 10.2), Section
11.3 (Warranties), Section 11.4 (Disclaimer of Representations and Warranties),
Section 11.5 (Limitation of Liability), Section 14.1 (Cooperation), Section
14.8 (Notices), Section 14.9 (Applicable Law), Section 14.10 (Arbitration),
Section 14.11 (Injunctive Relief) and Section 14.15 (Waiver).  

8.                                       Senior Secured Promissory Note.  The
Amended and Restated Senior Secured Promissory Note (the “Note”) by and between
Dyax and Genzyme effective as of May 31, 2002 shall remain in full force and
effect.  For the avoidance of doubt, the
termination of the Collaboration Agreement as set forth hereunder or any
subsequent collaboration among Dyax or any affiliate of Dyax or both such
entities and a third party shall not constitute an event of default under
Section 4(d) of the Note and Section 4(d) will be of no further effect under
the Note.

9.                                       Standstill.  For a period of [*] from the
Termination Effective Date (the “Standstill Period”), neither Genzyme nor any
of its subsidiaries (as such term is defined under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”)) will directly or indirectly:  (a) effect or publicly propose to effect, or
cause  any other person to effect or publicly
propose to effect, (i) any acquisition of any equity securities (or
beneficial ownership thereof) of Dyax; (ii) any tender or exchange offer,
merger or other business combination involving Dyax; (iii) any
recapitalization, restructuring, liquidation, dissolution or other similar extraordinary
transaction with respect to Dyax; or (iv) any “solicitation” of “proxies” (as
such terms are used in the proxy rules of the Securities and Exchange Commission)
or consents to vote any voting securities of Dyax; (b) form, or join, a “group”
(as defined under the Exchange Act) with respect to any equity securities of
Dyax; or (c)  enter into any discussions or arrangements with any third
party (other than Dyax) with respect to any of the foregoing.  For the avoidance of doubt, nothing in this
Section 9 shall prohibit Genzyme or any of its representatives from (a)
engaging in good faith, confidential negotiations with Dyax or any of Dyax’s
representatives regarding a possible business transaction involving Dyax and
Genzyme or (b) making proposals or requests to Dyax or taking other actions in
each case in connection with such negotiations. 
Notwithstanding anything to the contrary contained in this Section 9,
(i) Genzyme may own and may acquire shares or other ownership interests in any
mutual fund or similar entity that owns shares of stock of Dyax and (ii) the
restrictions set forth in this Section 9 shall immediately terminate and cease
to be of any further force or effect upon the commencement by any third party
of a tender or exchange offer that, if successful, would result in such

Confidential
materials omitted and filed separately with the Securities and Exchange

Commission.  An asterisk in brackets [*]
denotes such omission.

party
having ownership of fifty percent (50%) or more of any class or series of
securities of Dyax unless, within ten (10) days following such commencement,
the Board of Directors of Dyax has publicly announced that it recommends that
Dyax’s stockholders reject the offer; provided,
however, that such tender or exchange offer was not made in
violation of this Section 9.

10.                                 Post-Closing Covenant.  For
a period of [*] from the Termination Effective Date, neither Genzyme nor any of
its affiliates will enter into any licensing, collaboration or similar
agreement specifically for the prevention and/or treatment of hereditary,
acquired or drug-induced angioedema.

Confidential
materials omitted and filed separately with the Securities and Exchange

Commission.  An asterisk in brackets [*]
denotes such omission.

IN WITNESS WHEREOF, the parties hereto have caused this Termination
Agreement to be executed by their respective duly authorized representatives as
of the Termination Effective Date.

	
  GENZYME CORPORATION

  	
   

  	
   

  	
  DYAX CORP.

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
     /s/ Peter Wirth

  	
   

  	
  By:

  	
     /s/ Henry E. Blair

  	
   

  
	
  Name:

  	
  Peter Wirth

  	
   

  	
  Name:

  	
  Henry E. Blair

  
	
  Title:

  	
  Executive Vice President and Chief Legal

  	
   

  	
  Title:

  	
  Chairman and Chief Executive Officer

  
	
   

  	
  Officer

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  February 20,
  2007

  	
   

  	
  Date:

  	
  February 20,
  2007

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
     /s/ Michael S. Wyzga

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Michael S. Wyzga

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Executive Vice President and Chief Financial Officer

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  February 20,
  2007

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]